Ordering an Inivata test is simple and straightforward.

InVisionFirst-Lung is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) and structural variants in selected genes from DNA isolated from plasma samples from patients with non-small cell lung cancer (NSCLC). The test is intended to aid clinicians in treatment decisions for NSCLC patients.

Alterations associated with NSCLC which are currently most informative

  ALK
BRAF
  EGFR
  ERBB2 (HER2)
KRAS
  MET
  ROS1
  STK11

Alterations associated with:
a) an FDA approved drug for another tumor type,
b) inclusion or exclusion criteria for clinical trials and/or,
c) indicators for resistance to therapy.

AKT1
CCND1
  CDKN2A
CTNNB1
ESR1
  FGFR1
FGFR2
FGFR3
GATA3
GNA11
GNAQ
GNAS
HRAS
IDH1
IDH2
KIT
MAP2K1
MYC
NFE2L2
NRAS
NTRK1
NTRK3
PDGFRA
PIK3CA
PPP2R1A
  PTEN
  TP53
U2AF1
SNVs + Indels - Hotspot Regions
Fusions + SNVs + Indels
CNVs + SNVs + Indels
CNVs only
SNVs + Indels - Exon Coverage 70% for PTEN, 88-100% for TP53, STK11 and CDKN2A
  • 8 actionable genes relevant to advanced NSCLC  in a panel of 36 genes
  • 'Rule in' for EGFR, ALK, ROS1 FDA-approved therapies
  • 'Rule in' for presence of KRAS, STK11
  • 'Rule out' for KRAS, STK11
  • Currently 'Rule out' with potential to become 'Rule in' for HER2, MET and BRAF

Ordering an Inivata test is simple and straightforward.